Topic: New Therapy Targets Aggressive Chemotherapy-Resistant Breast Cancer
One of the hardest cancers to treat are tumors in the breast that do not express receptors for estrogen, progesterone, and human epidermal growth factor, dubbed triple negative breast cancers (TNBCs). Nearly 15% of all breast cancers diagnosed are TNBC. Resistant to conventional chemotherapy, TNBC is closely associated with relapse progression to stage 4 of the disease where the tumor metastasizes.
“Triple negative breast cancer is particularly challenging to treat because of the limited options beyond chemotherapy. There are fewer targeted therapies compared to other types of breast cancer. Many triple negative breast cancers also do not respond completely to our best chemotherapies for reasons that we are still trying to understand fully but cancer stem cells play an important role in this resistance,” says Hanna Irie, MD, PhD, associate professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai.
Earlier studies show breast cancer stem cells (BCSCs) are responsible for the initiation, progression and spread of TNBCs and contribute to resistance to chemotherapy. Therapies that eliminate these stem cells could therefore improve outcomes for high-risk patients, potentially leading to complete remission.
“Cancer stem cells are relatively quiescent and proliferate more slowly compared to non-stem cell cancer cells. Therefore, they escape the effects of chemotherapy, many of which rely on cell division to work, and persist. Cancer stem cells also have ways to pump out chemotherapy drugs. Cancer stem cells also have ways to avoid recognition by immune cells, which can compromise immunotherapies,” explains Irie.
In a new paper titled, “Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease“ published in Nature Communications, Irie and a team of scientists report that they have identified and validated of a new breast cancer therapy that targets and eliminates breast cancer stem cells.
“This study shows an exciting new therapeutic compound (108600) that can overcome chemotherapy resistance of triple negative breast cancer by targeting cancer stem cells that can drive this resistance. The study also shows how this drug can block and kill triple negative breast cancer that has already spread to other parts of the body, giving hope that this could be effective treatment for patients living with stage 4 triple negative breast cancer,” says Irie, co-corresponding author on the study.
Topic Discussed: New Therapy Targets Aggressive Chemotherapy-Resistant Breast Cancer